Sareum Holdings plc - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Sareum Holdings plc - Product Pipeline Review - 2014" provides data on the Sareum Holdings plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Sareum Holdings plc's corporate website, SEC filings, investor presentations and featured press releases, both from Sareum Holdings plc and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Sareum Holdings plc - Brief Sareum Holdings plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sareum Holdings plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Sareum Holdings plc with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Sareum Holdings plc's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Sareum Holdings plc's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Sareum Holdings plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Sareum Holdings plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Sareum Holdings plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Sareum Holdings plc and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Sareum Holdings plc Snapshot 5
Sareum Holdings plc Overview 5
Key Information 5
Key Facts 5
Sareum Holdings plc - Research and Development Overview 6
Key Therapeutic Areas 6
Sareum Holdings plc - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Sareum Holdings plc - Pipeline Products Glance 12
Sareum Holdings plc - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Sareum Holdings plc - Drug Profiles 14
Aurora + FLT3 Kinase Programme 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
CCT-244747 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Chk-1 Inhibitor Programme 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
FLT-3 Program 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Tyrosine Kinase2 Program 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
B-RAF Kinase Program 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
FASN Program 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Microtubule Binding Agents Programme 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Polo-Like Kinase-1 Program 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecules to Inhibit Aurora Kinase and ALK Kinase for Oncology 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
VEGFR-3 Inhibitors 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Sareum Holdings plc - Pipeline Analysis 26
Sareum Holdings plc - Pipeline Products by Therapeutic Class 26
Sareum Holdings plc - Pipeline Products by Target 27
Sareum Holdings plc - Pipeline Products by Route of Administration 29
Sareum Holdings plc - Pipeline Products by Molecule Type 30
Sareum Holdings plc - Pipeline Products by Mechanism of Action 31
Sareum Holdings plc - Recent Pipeline Updates 33
Sareum Holdings plc - Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Sareum Holdings plc, Key Information 5
Sareum Holdings plc, Key Facts 5
Sareum Holdings plc - Pipeline by Indication, 2014 7
Sareum Holdings plc - Pipeline by Stage of Development, 2014 9
Sareum Holdings plc - Monotherapy Products in Pipeline, 2014 10
Sareum Holdings plc - Combination Treatment Modalities in Pipeline, 2014 11
Sareum Holdings plc - Preclinical, 2014 12
Sareum Holdings plc - Discovery, 2014 13
Sareum Holdings plc - Pipeline by Therapeutic Class, 2014 26
Sareum Holdings plc - Pipeline by Target, 2014 28
Sareum Holdings plc - Pipeline by Route of Administration, 2014 29
Sareum Holdings plc - Pipeline by Molecule Type, 2014 30
Sareum Holdings plc - Pipeline Products by Mechanism of Action, 2014 32
Sareum Holdings plc - Recent Pipeline Updates, 2014 33
Sareum Holdings plc, Subsidiaries 35